Precision treatment of digestive system disorders

Applying specialist knowledge to develop small molecule antagonists of genetically-validated target GPR35
bt_bb_section_bottom_section_coverage_image
 

A competitor differentiated approach

Guided by human genetics, proprietary bioinformatics and pharmacology we are deploying GPR35 antagonism as a differentiated approach to treatment of disease

 

 

Founded upon a deep understanding of the biology of GPR35

We are a group of GPR35 and drug discovery specialists applying our knowledge to develop small molecule antagonists of the GPCR GPR35 for the treatment of serious digestive system disorders with high unmet clinical need

Founded upon a deep understanding of the biology of GPR35

Our Expertise

Established in 2021 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs

Latest News

ThirtyFiveBio Closes Bridge Round of Financing Highlighted by Strategic New Investment from AbbVie Ventures

ThirtyFiveBio Closes Bridge Round of Financing Highlighted by Strategic New Investment from AbbVie Ventures

ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of...
Read More
ThirtyFiveBio Awarded Second Grant by Innovate UK for £643k

ThirtyFiveBio Awarded Second Grant by Innovate UK for £643k

ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of...
Read More
£495k Grant Awarded by Innovate UK

£495k Grant Awarded by Innovate UK

ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of...
Read More